Skip to main content

Table 3 Multiple comparison test of levels of lipid parameters among treatment duration periods.

From: Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records

Treatment duration

TG (nmol/L)

TC (nmol/L)

 

LS mean ± SE

95% CI

p value

LS mean ± SE

95% CI

p value

Baseline

1.51 ± 0.05

1.42/1.61

reference

5.30 ± 0.04

5.21/5.39

reference

0~3M

1.52 ± 0.07

1.39/1.65

1

5.24 ± 0.05

5.14/5.35

0.5876

3~6M

1.53 ± 0.07

1.39/1.67

0.9984

5.30 ± 0.06

5.19/5.42

1

6~9M

1.61 ± 0.08

1.45/1.77

0.6205

5.26 ± 0.06

5.13/5.39

0.9223

9~12M

1.54 ± 0.08

1.36/1.72

0.9963

5.34 ± 0.07

5.20/5.48

0.9717

Treatment duration

HDL-C (nmol/L)

LDL-C (nmol/L)

 

LS mean ± SE

95% CI

p value

LS mean ± SE

95% CI

p value

Baseline

1.47 ± 0.02

1.42/1.52

reference

3.12 ± 0.05

3.02/3.21

reference

0~3M

1.45 ± 0.03

1.40/1.51

0.858

3.10 ± 0.05

2.99/3.21

0.9917

3~6M

1.45 ± 0.03

1.40/1.51

0.8875

3.05 ± 0.06

2.93/3.16

0.5653

6~9M

1.40 ± 0.03

1.34/1.46

0.0218*

3.11 ± 0.06

2.98/3.23

0.9999

9~12M

1.41 ± 0.03

1.34/1.47

0.1247

3.08 ± 0.07

2.95/3.22

0.9778

  1. TG: triglyceride, TC: total cholesterol, HDL-C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol, LS mean: least squares mean, SE: standard error, CI: confidence interval, p value: p value of treatment duration (compared with baseline, multiple-comparison test: Dunnett-Hsu post-hoc analysis), *: p < 0.05.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840